GDERF (GDERF OTCGREY) stock market data APIs
$184.0535
0(0%)
as of October 29, 2025
Try our APIs with
free plan!
GDERF Financial Data Overview
Price chart is built with
Anychart
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes ACTINICA, Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, Mirvaso, NEMLUVIO, Relfydess, Benzac, Loceryl, and TRI-LUMA in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Prev. Close
184.0535
Open
184.0535
High
184.0535
Low
184.0535
52 wk Range
81.8641-184.575
Market Cap
43 441 M
P/E Ratio
116.424
Shares Outstanding
235 M
Revenue
4 690 M
Dividends (Yield)
0.0009
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GDERF data using free add-ons & libraries
Get GDERF Fundamental Data
GDERF Fundamental data includes:
- Net Revenue: 4 690 M
- EBITDA: 988 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GDERF News
New
Galderma Delivers Record Net Sales of 3.737 Billion USD in the First Nine Months of 2025 and 15.0% Year-on-Year Growth at Constant Currency, Raises Full-Year Guidance
Ad hoc announcement pursuant to Art. 53 LR ZUG, Switzerland, October 23, 2025--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial ...
Galderma Group AG's (VTX:GALD) Intrinsic Value Is Potentially 78% Above Its Share Price
Key Insights The projected fair value for Galderma Group is CHF240 based on 2 Stage Free Cash Flow to Equity Current share price of CHF135 suggests Galderma Group is potentially 44% undervalued Our f...
Stock Futures Waver After Trump Unveils New Tariffs
U.S. stock futures wavered after President Trump unveiled new tariffs on drugs, trucks and furniture. Markets took the news in their stride. Continue Reading View Comments
European Pharmaceutical Stocks Fall On New Trump Tariffs
European pharmaceutical stocks fell, with Galderma and Novo Nordisk among those posting declines, after President Trump announced 100% tariffs on companies not building plants in the U.S. Continue Reading View Comments
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
